An interventional study of transcutaneous electroacupuncture in Scleroderma and Gastroparesis, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-26.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 153 studies in Scleroderma, Diffuse with a site in United States — 29 open to participants now, 39 under way, 5 of them phase 3. Scleroderma, Diffuse · United States.
Among the 153 studies in Scleroderma, Diffuse with a site in United States, this one is the 67th largest by enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2017, is one of 22 with no phase, and was the 83rd registered.
310 studies on the registry are indexed under Scleroderma, Diffuse; 76 are open to participants now.
Browse Scleroderma, Diffuse studies →29 of the 153 studies in Scleroderma, Diffuse with a site in United States are open now. Recruiting first, the newest first:
Miltenyi Biomedicine GmbH · Sites in United States
Ages 18+
Mediar Therapeutics · Sites in United States, Australia, France and 7 more countries
Ages 18+
Galderma R&D · Sites in United States, Switzerland
Ages 18+
Allogene Therapeutics · Sites in United States, Canada
Ages 18–74
Boston University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 55 Scleroderma, Diffuse studies recruiting now, 28 (51%) set no upper age limit and 20 (36%) stop at 75 or younger; 10 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
153 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 62 · Phase 3 18 · Phase 4 2
First in 1992; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 38 across 227 interventional studies indexed under Scleroderma, Diffuse.
Median enrollment 29 across the 120 interventional studies, 197 across the 32 observational. Of the 100 that completed or were terminated, 40 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 153 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins University is the lead sponsor of 1,816 studies on the registry; 315 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Johns Hopkins University has 9 studies filed under Scleroderma, Diffuse — fewer than ten, so there is no comparison to draw.
8 of the studies in Scleroderma, Diffuse with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06195072Scleroderma Research Foundation, Inc.Platform Clinical Study for Conquering Scleroderma | 2026-11 |
| NCT03276923Duke UniversityMaternal Autoimmune Disease Research Alliance (MADRA) Registry | 2027-01-01 |
| NCT06152172David PorterCARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 | 2027-02 |
| NCT06843239Zura Bio IncTibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 153 studies in Scleroderma, Diffuse with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An innovative method of needleless transcutaneous electroacupuncture (TEA) using a newly developed watch-size stimulator is proposed. Weak electrical current will be delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions. The stimulator can be attached to the skin near the acupuncture points and therefore daily activity of the patient does not need to be altered. Two experiments are designed to prove the feasibility of the proposed therapy for gastric complications of Scleroderma .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
for acute study: The experiment in patients will be performed in 4 randomized sessions on separate days (at least 3 days apart): one control session with sham-TEA and 3 TEA sessions at various parameters. TEA will be applied on both acupoints ST36 and PC6; the following sets of parameters will be tested for TEA at ST36: A) standard parameters: the set used in the previous SSc study: 25 Hz, 0.3ms, 2s-on and 3s-off; B) same as A but pulse width of 0.6ms; C) same as B but 0.1s-on and 0.4s-off. For TEA at PC6, 25 Hz will be replaced by 100Hz because TEA at PC6 is used to treat symptoms and 100Hz is believed to be better than 25Hz. The patient will be fasted overnight, and the test will last 2 hours (1 hour fasting and 1 hour postprandial).
Device: transcutaneous electroacupuncture
for chronic study: 2 weeks of Sham transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.
Device: transcutaneous electroacupuncture
for chronic study: 2 weeks of transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.
Device: transcutaneous electroacupuncture
Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions
Also known as: TEA
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
On the first visit; The validated UCLA SCTC GIT2.0 ("University of California at Los Angeles Scleroderma Clinical Trials Consortium Gastro-Intestinal Tract Instrument version 2.0") for SSc will be the primary outcome measurement; it includes 7 categories: reflux, distention and bloating, fecal soilage, diarrhea, social functioning, emotional well-being and constipation
Time frame: 1 day
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
On the second visit; The validated "University of California at Los Angeles Scleroderma Clinical Trials Consortium Gastro-Intestinal Tract Instrument version 2.0" (UCLA SCTC GIT2.0) for SSc will be the primary outcome measurement; it includes 7 categories: reflux, distention and bloating, fecal soilage, diarrhea, social functioning, emotional well-being and constipation
Time frame: 28 days
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
On the third visit; The validated UCLA SCTC GIT2.0 ("University of California at Los Angeles Scleroderma Clinical Trials Consortium Gastro-Intestinal Tract Instrument version 2.0") for SSc will be the primary outcome measurement; it includes 7 categories: reflux, distention and bloating, fecal soilage, diarrhea, social functioning, emotional well-being and constipation
Time frame: 42 days
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
The validated UCLA SCTC GIT2.0 ("University of California at Los Angeles Scleroderma Clinical Trials Consortium Gastro-Intestinal Tract Instrument version 2.0") for SSc will be the primary outcome measurement; it includes 7 categories: reflux, distention and bloating, fecal soilage, diarrhea, social functioning, emotional well-being and constipation
Time frame: 70 days
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
Scleroderma Health Assessment Questionnaire will be used to assess SSc symptoms
Time frame: 1 day
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
Scleroderma Health Assessment Questionnaire will be used to assess SSc symptoms
Time frame: 28 days
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
Scleroderma Health Assessment Questionnaire will be used to assess SSc symptoms
Time frame: 42 days
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
Scleroderma Health Assessment Questionnaire will be used to assess SSc symptoms
Time frame: 70 days
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
SF-36 questionnaire will be used to assess general quality of life
Time frame: 1 day
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
SF-36 questionnaire will be used to assess general quality of life
Time frame: 28 days
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
SF-36 questionnaire will be used to assess general quality of life
Time frame: 42 days
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
SF-36 questionnaire will be used to assess general quality of life
Time frame: 70 days
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
a validated method including 9 symptoms will be used to assess GI symptoms
Time frame: 1 day
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
a validated method including 9 symptoms will be used to assess GI symptoms
Time frame: 28 days
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
a validated method including 9 symptoms will be used to assess GI symptoms
Time frame: 42 days
effect of TEA on symptoms in Systemic Sclerosis (SSc) patients
a validated method including 9 symptoms will be used to assess GI symptoms
Time frame: 70 days
effects of TEA on gastric motility
visit 1 in acute phase; gastric slow waves recording
Time frame: 1 week
effects of TEA on gastric motility
visit 2 in acute phase; gastric slow waves recording
Time frame: 2 weeks
effects of TEA on gastric motility
visit 3 in acute phase; gastric slow waves recording
Time frame: 3 weeks
effects of TEA on gastric motility
visit 4 in acute phase; gastric slow waves recording
Time frame: 4 weeks
effects of TEA on autonomic function
visit 1 in acute phase; heart rate variability recording
Time frame: 1 week
effects of TEA on autonomic function
visit 2 in acute phase; heart rate variability recording
Time frame: 2 weeks
effects of TEA on autonomic function
visit 3 in acute phase; heart rate variability recording
Time frame: 3 weeks
effects of TEA on autonomic function
visit 4 in acute phase; heart rate variability recording
Time frame: 4 weeks
effects of TEA on gastric motility
visit 1 in chronic phase; gastric slow waves recording
Time frame: 1 day
effects of TEA on gastric motility
visit 2 in chronic phase; gastric slow waves recording
Time frame: 28 days
effects of TEA on gastric motility
visit 3 in chronic phase; gastric slow waves recording
Time frame: 42 days
effects of TEA on gastric motility
visit 4 in chronic phase; gastric slow waves recording
Time frame: 70 days
effects of TEA on gastric motility
visit 1 in chronic phase; breath test will be used to assess gastric emptying
Time frame: 1 day
effects of TEA on gastric motility
visit 2 in chronic phase; breath test will be used to assess gastric emptying
Time frame: 28 days
effects of TEA on gastric motility
visit 3 in chronic phase; breath test will be used to assess gastric emptying
Time frame: 42 days
effects of TEA on gastric motility
visit 4 in chronic phase; breath test will be used to assess gastric emptying
Time frame: 70 days
effects of TEA on autonomic function
visit 1 in chronic phase; heart rate variability recording
Time frame: 1 day
effects of TEA on autonomic function
visit 2 in chronic phase; heart rate variability recording
Time frame: 28 days
effects of TEA on autonomic function
visit 3 in chronic phase; heart rate variability recording
Time frame: 42 days
effects of TEA on autonomic function
visit 4 in chronic phase; heart rate variability recording
Time frame: 70 days
effects of TEA on autonomic function
visit 1 in chronic phase; Composite Autonomic Symptoms Score (COMPASS) 31 survey will be used to assess autonomic function
Time frame: 1 day
effects of TEA on autonomic function
visit 2 in chronic phase; Composite Autonomic Symptoms Score (COMPASS) 31 survey will be used to assess autonomic function
Time frame: 28 days
effects of TEA on autonomic function
visit 3 in chronic phase; Composite Autonomic Symptoms Score (COMPASS) 31 survey will be used to assess autonomic function
Time frame: 42 days
effects of TEA on autonomic function
visit 1 in chronic phase; Composite Autonomic Symptoms Score (COMPASS) 31 survey visit 4 in chronic phase; will be used to assess autonomic function
Time frame: 70 days
effects of TEA on autonomic function
baseline before the study; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.
Time frame: 1 day
effects of TEA on autonomic function
baseline before the study; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.
Time frame: 28 days
effects of TEA on autonomic function
baseline before the study; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.
Time frame: 42 days
effects of TEA on autonomic function
baseline before the study; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.
Time frame: 70 days
effects of TEA on autonomic function
30 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.
Time frame: 1 day
effects of TEA on autonomic function
30 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.
Time frame: 28 days
effects of TEA on autonomic function
30 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.
Time frame: 42 days
effects of TEA on autonomic function
30 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.
Time frame: 70 days
effects of TEA on autonomic function
60 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.
Time frame: 1 day
effects of TEA on autonomic function
60 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.
Time frame: 28 days
effects of TEA on autonomic function
60 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.
Time frame: 42 days
effects of TEA on autonomic function
60 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.
Time frame: 70 days
effects of TEA on autonomic function
baseline before the study; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.
Time frame: 1 day
effects of TEA on autonomic function
baseline before the study; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.
Time frame: 28 days
effects of TEA on autonomic function
baseline before the study; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.
Time frame: 42 days
effects of TEA on autonomic function
baseline before the study; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.
Time frame: 70 days
effects of TEA on autonomic function
30 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.
Time frame: 1 day
effects of TEA on autonomic function
30 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.
Time frame: 28 days
effects of TEA on autonomic function
30 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.
Time frame: 42 days
effects of TEA on autonomic function
30 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.
Time frame: 70 days
effects of TEA on autonomic function
60 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.
Time frame: 1 day
effects of TEA on autonomic function
60 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.
Time frame: 28 days
effects of TEA on autonomic function
60 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.
Time frame: 42 days
effects of TEA on autonomic function
60 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; vasoactive intestinal peptide (VIP)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; vasoactive intestinal peptide (VIP)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; vasoactive intestinal peptide (VIP)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; vasoactive intestinal peptide (VIP)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; vasoactive intestinal peptide (VIP)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; vasoactive intestinal peptide (VIP)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; vasoactive intestinal peptide (VIP)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; vasoactive intestinal peptide (VIP)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; vasoactive intestinal peptide (VIP)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; vasoactive intestinal peptide (VIP)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; vasoactive intestinal peptide (VIP)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; vasoactive intestinal peptide (VIP)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interleukin-10 (IL-10)
Time frame: day 1
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interleukin-10 (IL-10)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interleukin-10 (IL-10)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interleukin-10 (IL-10)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interleukin-10 (IL-10)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interleukin-10 (IL-10)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interleukin-10 (IL-10)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interleukin-10 (IL-10)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interleukin-10 (IL-10)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interleukin-10 (IL-10)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interleukin-10 (IL-10)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interleukin-10 (IL-10)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interferon α(IFNα)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interferon α(IFNα)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interferon α(IFNα)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interferon α(IFNα)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interferon α(IFNα)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interferon α(IFNα)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interferon α(IFNα)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interferon α(IFNα)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interferon α(IFNα)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interferon α(IFNα)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interferon α(IFNα)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interferon α(IFNα)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interleukin-1 beta (IL-1β)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interleukin-1 beta (IL-1β)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interleukin-1 beta (IL-1β)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interleukin-1 beta (IL-1β)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interleukin-1 beta (IL-1β)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interleukin-1 beta (IL-1β)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interleukin-1 beta (IL-1β)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interleukin-1 beta (IL-1β)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interleukin-1 beta (IL-1β)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interleukin-1 beta (IL-1β)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interleukin-1 beta (IL-1β)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interleukin-1 beta (IL-1β)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interleukin-6 (IL-6)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interleukin-6 (IL-6)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interleukin-6 (IL-6)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; interleukin-6 (IL-6)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interleukin-6 (IL-6)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interleukin-6 (IL-6)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interleukin-6 (IL-6)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; interleukin-6 (IL-6)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interleukin-6 (IL-6)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interleukin-6 (IL-6)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interleukin-6 (IL-6)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; interleukin-6 (IL-6)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; tumor necrosis factor alpha(TNFα)
Time frame: day 1
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; tumor necrosis factor alpha(TNFα)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; tumor necrosis factor alpha(TNFα)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
baseline before the study; tumor necrosis factor alpha(TNFα)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; tumor necrosis factor alpha(TNFα)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; tumor necrosis factor alpha(TNFα)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; tumor necrosis factor alpha(TNFα)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
30 minutes after the testing meal; tumor necrosis factor alpha(TNFα)
Time frame: 70 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; tumor necrosis factor alpha(TNFα)
Time frame: 1 day
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; tumor necrosis factor alpha(TNFα)
Time frame: 28 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; tumor necrosis factor alpha(TNFα)
Time frame: 42 days
effects of TEA on GI hormones and inflammatory cytokine
60 minutes after the testing meal; tumor necrosis factor alpha(TNFα)
Time frame: 70 days
Plan to share: Undecided — haven't decided yet.
No publications or documents are linked to this record.
Ran from Feb 2017 to primary completion in Jun 2019, 28 months.
Of 51 non-industry interventional studies with no phase under Scleroderma, Diffuse, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's 28 months is above that.
Counting every sponsor, half of 53 studies reached it within 16 months; a quarter within 4 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.